MEN1 and multiple endocrine neoplasia type 1: Meanwhile, there were four MEN1 patients who received Lanreotide or Octreotide therapy due to gastrointestinal and/or pancreatic NETs and one acromegaly patient with excluded MEN1 syndrome by genetic testing, who was treated by Lanreotide due to pituitary disease persistence after transsphenoidal surgery.